HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Overrepresentation of 17q22-qter and 22q13 in dermatofibrosarcoma protuberans but not in dermatofibroma: a comparative genomic hybridization study.

Abstract
Histopathological differentiation between dermatofibrosarcoma protuberans (DFSP) and dermatofibroma (DF) is often difficult, because both neoplasms share some clinical features and the presence of a storiform pattern. In the present study, we investigated the usefulness of comparative genomic hybridization (CGH) in the diagnosis of these entities by examining 12 DFSP and 12 DF cases. The most frequent DNA sequence copy number changes detected in 10 (83%) of 12 DFSP cases (mean, 1.9 aberrations/tumor; range, 0-3) consisted of gains of 17q22-qter (10 tumors), 22q13 (nine tumors), and 8q24.1-qter (three tumors). High-level amplification, which was detected in three tumors, was seen only in chromosome 17, with 17q23-q25 as the minimal common region. Loss of DNA sequences was not found in DFSP cases. In contrast, two (17%) of the 12 DF cases (mean, 0.5 aberrations/tumor; range, 0-4) showed DNA sequence copy number changes, although recurrent gains and losses and high-level amplifications were not observed. Gains were more common than losses in DF. Overrepresentation of 17q and 22q sequences was a common finding in DFSP but not in DF. Thus, CGH seems to be useful for distinguishing DFSP from DF in most cases.
AuthorsJun Nishio, Hiroshi Iwasaki, Yuko Ohjimi, Masako Ishiguro, Teruto Isayama, Masatoshi Naito, Akinori Iwashita, Masahiro Kikuchi
JournalCancer genetics and cytogenetics (Cancer Genet Cytogenet) Vol. 132 Issue 2 Pg. 102-8 (Jan 15 2002) ISSN: 0165-4608 [Print] United States
PMID11850069 (Publication Type: Comparative Study, Journal Article)
Topics
  • Adult
  • Aged
  • Chromosomes, Human, Pair 17
  • Chromosomes, Human, Pair 22
  • Dermatofibrosarcoma (genetics)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nucleic Acid Hybridization

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: